L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata

Neurobiology of Disease

Volumn 41, Issue 1, 2011, Pages 51-61

  Rangel Barajas, Claudia ^a   Silva, Isaac ^b   Lopéz Santiago, Luz María ^a   Aceves, Jorge ^a   Erlij, David ^c   Florán, Benjamín ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

^c SUNY Downstate Medical Center   (United States)

Author keywords

Basal ganglia; CAMP; GABA release; Hemiparkinsonism; L DOPA; Substantia nigra

Indexed keywords

4 AMINOBUTYRIC ACID; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; ADENYLATE CYCLASE TYPE V; ADENYLATE CYCLASE TYPE VI; BENSERAZIDE; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; LEVODOPA METHYL ESTER; OXIDOPAMINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN SLICE; CONTROLLED STUDY; DENERVATION; DISEASE SEVERITY; DYSKINESIA; ENZYME REGULATION; GABAERGIC TRANSMISSION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA RETICULATA; TREATMENT DURATION;

ADENYLATE CYCLASE; ANIMALS; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; GAMMA-AMINOBUTYRIC ACID; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 78349305929     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.08.018     Document Type: Article

References (40)

1. Alexander S.P. The measurement of cyclic AMP levels in biological preparations. Methods Mol. Biol. 1995, 41:78-89.
2. Arias-Montaño J.A., Floran B., Floran L., Aceves J., Young J.M. Dopamine D(1) receptor facilitation of depolarization-induced release of gamma-amino-butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels. Synapse 2007, 61:310-319.
3. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., Bioulac B., Gross C., Fisone G., Bloch B., Bezard E. Increased D1 receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
4. Auker C.R., Meszler R.M., Carpenter D.O. Apparent discrepancy between single-unit activity and deoxyglucose labeling in optic tectum of the rattlesnake. J. Neurophysiol. 1983, 49:1504-1516.
5. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
6. Butkerait P., Friedman E. Repeated reserpine increases striatal dopamine receptor and guanine nucleotide binding protein RNA. J. Neurochem. 1993, 60:566-571.
7. Cai G., Wang H.Y., Friedman E. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 2002, 302:1105-1112.
8. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 2007, 30:236-243.
9. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
10. Cenci M.A., Tranberg A., Andersson M., Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment. Neuroscience 1999, 94:515-527.
11. Corvol J.C., Muriel M.P., Valjent E., Feger J., Hanoun N., Girault J.A., Hirsch E.C., Herve D. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J. Neurosci. 2004, 24:7007-7014.
12. Darmopil S., Matin A., Ruiz I., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation. Biol. Psychiatry 2009, 66:603-613.
13. Fiorentini C., Rizzetti M.C., Busi C., Bontempi S., Collo G., Spano P., Missale C. Loss of synaptic D1 dopamine/N-methyl-d-aspartate glutamate receptor complexes in l-DOPA-induced dyskinesia in the rat. Mol. Pharmacol. 2006, 69:805-812.
14. Floran B., Aceves J., Sierra A., Martinez-Fong D. Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci. Lett. 1990, 116:136-140.
15. Greengard P., Allen P., Nairn A. Beyond the dopamine receptor: the DARP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
16. Guerrero-Barrera A.L., Garcia-Cuellar C.M., Villalba J.D., Segura-Nieto M., Gomez-Lojero C., Reyes M.E., Hernandez J.M., Garcia R.M., de la Garza M. Actin-related proteins in Anabaena spp. and Escherichia coli. Microbiology 1996, 142:1133-1140.
17. Hagell P., Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov. Disord. 1999, 14:448-455.
18. Hudson J.L., Levin D.R., Hoffer B.J. A 16-channel automated rotometer system for reliable measurement of turning behavior in 6-hydroxydopamine lesioned and transplanted rats. Cell Transplant. 1993, 2:507-514.
19. Insel P.A., Ostrom R.S. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell. Mol. Neurobiol. 2003, 23:305-314.
20. Iwamoto T., Okumura S., Iwatsubo K., Kawabe J., Ohtsu K., Sakai I., Hashimoto Y., Izumitani A., Sango K., Ajiki K., et al. Motor dysfunction in type 5 adenylyl cyclase-null mice. J. Biol. Chem. 2003, 278:16936-16940.
21. Johnston T.H., Lee J., Gomez-Ramirez J., Fox S.H., Brotchie J.M. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp. Neurol. 2005, 191:243-250.
22. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 2007, 101:483-497.
23. Mitchell I.J., Boyce S., Sambrook M.A., Crossman A.R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992, 115:809-824.
24. Mons N., Cooper D.M. Selective expression of one Ca(2+)-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions. Brain Res. Mol. Brain Res. 1994, 22:236-244.
25. Napolitano M., Centonze D., Calce A., Picconi B., Spiezia S., Gulino A., Bernardi G., Calabresi P. Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol. Dis. 2002, 10:387-395.
26. Nava-Asbell C., Paz-Bermudez F., Erlij D., Aceves J., Floran B. GABA(B) receptor activation inhibits dopamine D1 receptor-mediated facilitation of GABA release in substantia nigra pars reticulata. Neuropharmacology 2007, 53:631-637.
27. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000, 23:S8-S19.
28. Ochi M., Shiozaki S., Kase H. l-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease. Synapse 2004, 52:163-165.
29. Onda T., Hashimoto Y., Nagai M., Kuramochi H., Saito S., Yamazaki H., Toya Y., Sakai I., Homcy C.J., Nishikawa K., et al. Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J. Biol. Chem. 2001, 276:47785-47793.
30. Paxinos, G., Watson, C., 1997. The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
31. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
32. Rangel Barajas C.R., Siva I., Aceves J., Erlij D., Floran B. l-DOPA induced dyskinesia modify expression and activity of adenylyl cyclase V/VI in striato-nigral terminals of the rat. Neurosci. Abstr. 2009, 630.k7.
33. Rangel-Barajas C., Silva I., Garcia-Ramirez M., Sanchez-Lemus E., Floran L., Aceves J., Erlij D., Floran B. 6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat. Neuropharmacology 2008, 55:704-711.
34. Rao A.S., Bodenheimer R.E., Davis T.L., Li R., Voight C., Dawant B.M. Quantifying drug induced dyskinesia in Parkinson's disease patients using standardized videos. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2008 2008, 1769-1772.
35. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J., Hervé D., Greengard P., Fisone G. Critical involment of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA induced dyskinesia. J. Neurosci. 2007, 27:6995-7005.
36. Santini E., Alcacer C., Cacciatore S., Heiman M., Hervé D., Greengard P., Girault J., Valjent E., Fisone G. l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J. Neurochem. 2009, 108:621-633.
37. Schwartz W.J., Smith C.B., Davidsen L., Savaki H., Sokoloff L., Mata M., Fink D.J., Gainer H. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979, 205:723-725.
38. Soghomonian J.J., Laprade N. Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of Parkinsonian monkeys. Synapse 1997, 27:122-132.
39. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007, 30:228-235.
40. Windels F., Kiyatkin E.A. Dopamine action of the substantia nigra pars reticulta: iontophoretic studies in awake, unrestrained rats. Eur. J. Neurosci. 2006, 24:1385-1394.